Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Molecular Interactions of a DNA Modifying Enzyme APOBEC3F Catalytic Domain with a Single-Stranded DNA.

Fang Y, Xiao X, Li SX, Wolfe A, Chen XS.

J Mol Biol. 2018 Jan 5;430(1):87-101. doi: 10.1016/j.jmb.2017.11.007. Epub 2017 Nov 27.

PMID:
29191651
2.

Reassessing APOBEC3G Inhibition by HIV-1 Vif-Derived Peptides.

Richards CM, Li M, Perkins AL, Rathore A, Harki DA, Harris RS.

J Mol Biol. 2017 Jan 6;429(1):88-96. doi: 10.1016/j.jmb.2016.11.012. Epub 2016 Nov 22.

3.

Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation.

Delviks-Frankenberry KA, Nikolaitchik OA, Burdick RC, Gorelick RJ, Keele BF, Hu WS, Pathak VK.

PLoS Pathog. 2016 May 17;12(5):e1005646. doi: 10.1371/journal.ppat.1005646. eCollection 2016 May.

4.

Functional Upregulation of the DNA Cytosine Deaminase APOBEC3B by Polyomaviruses.

Verhalen B, Starrett GJ, Harris RS, Jiang M.

J Virol. 2016 Jun 24;90(14):6379-86. doi: 10.1128/JVI.00771-16. Print 2016 Jul 15.

5.

Autonomous immunity in mucosal epithelial cells: fortifying the barrier against infection.

Ross KF, Herzberg MC.

Microbes Infect. 2016 Jun;18(6):387-398. doi: 10.1016/j.micinf.2016.03.008. Epub 2016 Mar 19. Review.

6.

A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins.

Suryawanshi GW, Hoffmann A.

J Theor Biol. 2015 Dec 7;386:89-104. doi: 10.1016/j.jtbi.2015.08.032. Epub 2015 Sep 16.

7.

APOBECs and virus restriction.

Harris RS, Dudley JP.

Virology. 2015 May;479-480:131-45. doi: 10.1016/j.virol.2015.03.012. Epub 2015 Mar 26. Review.

8.

N-linked glycosylation protects gammaretroviruses against deamination by APOBEC3 proteins.

Rosales Gerpe MC, Renner TM, Bélanger K, Lam C, Aydin H, Langlois MA.

J Virol. 2015 Feb;89(4):2342-57. doi: 10.1128/JVI.03330-14. Epub 2014 Dec 10.

9.

Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.

Armitage AE, Deforche K, Welch JJ, Van Laethem K, Camacho R, Rambaut A, Iversen AK.

J Virol. 2014 Nov;88(21):12882-94. doi: 10.1128/JVI.01460-14. Epub 2014 Aug 27.

10.

Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, Pathak VK.

J Mol Biol. 2014 Mar 20;426(6):1220-45. doi: 10.1016/j.jmb.2013.10.033. Epub 2013 Nov 2. Review.

11.

The APOBEC3 family of retroelement restriction factors.

Refsland EW, Harris RS.

Curr Top Microbiol Immunol. 2013;371:1-27. doi: 10.1007/978-3-642-37765-5_1. Review.

12.

APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure.

Holtz CM, Sadler HA, Mansky LM.

Nucleic Acids Res. 2013 Jul;41(12):6139-48. doi: 10.1093/nar/gkt246. Epub 2013 Apr 24.

13.

Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold.

Olson ME, Li M, Harris RS, Harki DA.

ChemMedChem. 2013 Jan;8(1):112-7. doi: 10.1002/cmdc.201200411. Epub 2012 Nov 23.

14.

Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components.

Zhou X, Evans SL, Han X, Liu Y, Yu XF.

PLoS One. 2012;7(3):e33495. doi: 10.1371/journal.pone.0033495. Epub 2012 Mar 30.

15.

APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.

Armitage AE, Deforche K, Chang CH, Wee E, Kramer B, Welch JJ, Gerstoft J, Fugger L, McMichael A, Rambaut A, Iversen AK.

PLoS Genet. 2012;8(3):e1002550. doi: 10.1371/journal.pgen.1002550. Epub 2012 Mar 22.

16.

First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G.

Li M, Shandilya SM, Carpenter MA, Rathore A, Brown WL, Perkins AL, Harki DA, Solberg J, Hook DJ, Pandey KK, Parniak MA, Johnson JR, Krogan NJ, Somasundaran M, Ali A, Schiffer CA, Harris RS.

ACS Chem Biol. 2012 Mar 16;7(3):506-17. doi: 10.1021/cb200440y. Epub 2012 Jan 17.

17.

Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.

Zhang W, Du J, Yu K, Wang T, Yong X, Yu XF.

J Virol. 2010 Dec;84(24):12903-13. doi: 10.1128/JVI.01632-10. Epub 2010 Oct 6.

18.

Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.

Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, Malim MH, Wolinsky SM.

J Virol. 2010 Oct;84(19):10402-5. doi: 10.1128/JVI.01223-10. Epub 2010 Jul 21.

19.

Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif.

Lassen KG, Wissing S, Lobritz MA, Santiago M, Greene WC.

J Biol Chem. 2010 Sep 17;285(38):29326-35. doi: 10.1074/jbc.M110.154054. Epub 2010 Jul 12.

20.

APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Sadler HA, Stenglein MD, Harris RS, Mansky LM.

J Virol. 2010 Jul;84(14):7396-404. doi: 10.1128/JVI.00056-10. Epub 2010 May 12.

Supplemental Content

Support Center